MicroRNA-29a (miR-29a) (miR-29a)

The target refers to the specific sequences within the 3' untranslated regions (UTRs) of messenger RNAs (mRNAs) that are recognized and bound by MicroRNA-29a (miR-29a). MicroRNA-29a is a key regulatory non-coding RNA that acts as a master suppressor of the fibrotic response by targeting the 3' UTRs of multiple mRNAs involved in extracellular matrix (ECM) production [Maurer et al., 2010]. Its recognition sites are found on mRNAs for collagen types I, III, and IV, as well as elastin and fibrillin-1, where miR-29a binding leads to translational inhibition or mRNA degradation [van Rooij et al., 2008]. In addition to its anti-fibrotic role, miR-29a modulates inflammatory pathways by regulating the expression of cytokines and signaling molecules like interferon-gamma and members of the NF-kB pathway [Brain et al., 2013]. Pathological downregulation of miR-29a is a hallmark of various fibrotic diseases, including systemic sclerosis, pulmonary fibrosis, and myocardial infarction, making the restoration of its activity a significant therapeutic goal [Gallant-Behm et al., 2019]. Therapeutic agents such as Remlarsen (MRG-201) are synthetic miR-29a mimics designed to bind these recognition sites and reduce the expression of overactive fibrotic and inflammatory genes [ClinicalTrials.gov, NCT02603224]. The specificity of miR-29a for these 3' UTR sites allows for the simultaneous downregulation of a broad network of genes that drive tissue scarring and chronic inflammation. However, the multi-target nature of miR-29a also presents challenges, as unintended gene silencing in non-target tissues can lead to off-target effects. Current research focuses on optimizing delivery systems, such as lipid nanoparticles or conjugated oligonucleotides, to ensure the mimic reaches the affected tissues effectively. Monitoring miR-29a levels and downstream ECM proteins serves as a vital biomarker strategy for assessing treatment efficacy in clinical trials.

Other names

hsa-miR-29aMIR29AMicroRNA 29a-3pmiR-29a-3p

Agonism (miRNA mimicry) to induce post-transcriptional gene silencing of pro-fibrotic and inflammatory mRNAs by binding to their 3' UTRs.